Cerebrospinal Fluid Markers of Alzheimer’s Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The immune response in Alzheimer's disease (AD) involves activation of microglia which may remove amyloid-β (Aβ). However, overproduction of inflammatory compounds may exacerbate neural damage in AD. AD pathology accumulates years before diagnosis, yet the extent to which neuroinflammation is involved in the earliest disease stages is unknown. OBJECTIVE: To determine whether neuroinflammation exacerbates neural damage in preclinical AD. METHODS: We utilized cerebrospinal fluid (CSF) and magnetic resonance imaging collected in 192 asymptomatic late-middle-aged adults (mean age = 60.98 years). Neuroinflammatory markers chitinase-3-like protein 1 (YKL-40) and monocyte chemoattractant protein-1 (MCP-1) in CSF were utilized as markers of neuroinflammation. Neural cell damage was assessed using CSF neurofilament light chain protein (NFL), CSF total tau (T-Tau), and neural microstructure assessed with diffusion tensor imaging (DTI). With regard to AD pathology, CSF Aβ42 and tau phosphorylated at threonine 181 (P-Tau181) were used as markers of amyloid and tau pathology, respectively. We hypothesized that higher YKL-40 and MCP-1 in the presence of AD pathology would be associated with higher NFL, T-Tau, and altered microstructure on DTI. RESULTS: Neuroinflammation was associated with markers of neural damage. Higher CSF YKL-40 was associated with both higher CSF NFL and T-Tau. Inflammation interacted with AD pathology, such that greater MCP-1 and lower Aβ42 was associated with altered microstructure in bilateral frontal and right temporal lobe and that greater MCP-1 and greater P-Tau181 was associated with altered microstructure in precuneus. CONCLUSION: Inflammation may play a role in neural damage in preclinical AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Pathological changes associated with AD appear years before the onset of clinically relevant symptoms [50].”
The basis of anisotropic water diffusion in the nervous system—A technical review.
Beaulieu, C. (2002) · NMR in Biomedicine · doi:10.1002/nbm.782 · Cited by 4,628 · cited 1×
“and mean diffusivity (MD), a measure of isotropic diffusion that is sensitive to cellular structure, necrosis, and edema [33,34].”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Diffusion tensor imaging of the brain
Alexander, A. L., Lee, J. E., Lazar, M., & Field, A. S. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.05.011 · Cited by 2,747 · cited 1×
“and mean diffusivity (MD), a measure of isotropic diffusion that is sensitive to cellular structure, necrosis, and edema [33,34].”
Self-citationMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557 · cited 1×
“While the immune response in AD may released by chronically active microglia may also contribute to neuronal damage by causing injury and toxicity to neurons (cid:2) [8, 12].”
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404 · cited 1×
“Medial temporal lobes are affected early in AD, and hippocampal volume is reduced in AD, MCI, and prodromal stages of the disease [25, 26].”
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Combs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721 · cited 1×
“In cell culture, microglia activated by A have been shown to release reactive oxygen species, TNF- , and several other molecules that are known to induce apoptosis [13, 14].”
Bozzali, M. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.742 · Cited by 568
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · cited 1×
“While CSF A 42 generally declines during the progression of AD, studies in individuals with PSEN1 mutation show elevated CSF A 42 levels compared to non-carriers in the asymptomatic stage of the disease [76].”
Douaud, G., Jbabdi, S., Behrens, T. E. J., Menke, R. A., Gass, A., Monsch, A. U., Rao, A., Whitcher, B., Kindlmann, G., Matthews, P. M., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.12.008 · Cited by 514
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504 · cited 2×
“These two proteins are elevated in pre-clinical AD, mild cognitive impairment (MCI), and early AD [4, 15–18].”
Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 1×
“Several proinflammatory cytokines, chemokines, and complement proteins are elevated in the AD brain and both human and animal studies suggest inflammation may occur early in the AD process [3–7].”
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study
Medina, D., deToledo-Morrell, L., Urresta, F., Gabrieli, J. D. E., Moseley, M., Fleischman, D., Bennett, D. A., Leurgans, S., Turner, D. A., & Stebbins, G. T. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.026 · Cited by 492 · cited 1×
“Of relevance to AD, DTI studies have shown neural damage across the spectrum of AD, MCI, and preclinical disease [27–38].”
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368 · cited 1×
“Samples were analyzed for T-tau and Aβ42 using commercially available enzyme-linked immunosorbent assay (ELISA) methods (INNOTEST assays, Fujiurebio, Ghent Belgium) as described previously in detail [43].”
Self-citationDecreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., & Van Leuven, F. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-22 · Cited by 309 · cited 1×
“A and tau [8, 78].”
Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030525 · Cited by 277
Neuronal damage in brain inflammation
Aktas, O., Ullrich, O., Infante-Duarte, C., Nitsch, R., & Zipp, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.2.185 · Cited by 249 · cited 1×
“Axonal degeneration has been hypothesized to be an early feature of the AD process [54], although the specific effect of neuroinflammation on axonal degeneration is incompletely characterized [55].”
ISHIZUKA, K., KIMURA, T., IGATA‐YI, R., KATSURAGI, S., TAKAMATSU, J., & MIYAKAWA, T. (1997) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1997.tb02375.x · Cited by 245 · cited 1×
“Cellular studies show that human monocytes and activated microglia produce MCP-1 in response to A fragments and larger amyloid plaques in order to recruit additional immune cells [58, 59].”
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209
Ryan, N. S., Keihaninejad, S., Shakespeare, T. J., Lehmann, M., Crutch, S. J., Malone, I. B., Thornton, J. S., Mancini, L., Hyare, H., Yousry, T., et al. (2013) · Brain · doi:10.1093/brain/awt065 · Cited by 205
Gray and white matter changes in Alzheimer's disease: a diffusion tensor imaging study
Rose, S. E., Janke PhD, A. L., & Chalk, J. B. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21231 · Cited by 178 · cited 1×
“Of relevance to AD, DTI studies have shown neural damage across the spectrum of AD, MCI, and preclinical disease [27–38].”
NSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Racine, A. M., Adluru, N., Alexander, A. L., Christian, B. T., Okonkwo, O. C., Oh, J., Cleary, C. A., Birdsill, A., Hillmer, A. T., Murali, D., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.02.001 · Cited by 136
Self-citationSheffield, L. G., Marquis, J. G., & Berman, N. E. J. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01037-5 · Cited by 96
Bendlin, B. B., Carlsson, C. M., Johnson, S. C., Zetterberg, H., Blennow, K., Willette, A. A., Okonkwo, O. C., Sodhi, A., Ries, M. L., Birdsill, A. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037720 · Cited by 91
Self-citationAdluru, N., Destiche, D. J., Lu, S. Y.-F., Doran, S. T., Birdsill, A. C., Melah, K. E., Okonkwo, O. C., Alexander, A. L., Dowling, N. M., Johnson, S. C., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.04.008 · Cited by 85
Self-citationEffects of APOE on brain white matter microstructure in healthy adults
Westlye, L. T., Reinvang, I., Rootwelt, H., & Espeseth, T. (2012) · Neurology · doi:10.1212/wnl.0b013e3182735c9c · Cited by 84
Role of Family History for Alzheimer Biomarker Abnormalities in the Adult Children Study
Xiong, C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.208 · Cited by 56 · cited 1×
“Of relevance to AD, DTI studies have shown neural damage across the spectrum of AD, MCI, and preclinical disease [27–38].”
Voxel-based diffusion tensor imaging of an APP/PS1 mouse model of Alzheimer’s disease.
Shu, X., Qin, Y.-Y., Zhang, S., Jiang, J.-J., Zhang, Y., Zhao, L.-Y., Shan, D., & Zhu, W.-Z. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8418-6 · Cited by 41
Cited by
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.057 · Cited by 622
“Several biomarkers have shown association with AD, including proteins measured in the CSF (Melah et al., 2016), brain atrophy, particularly in the hippocampus (Frisoni et al., 2002) and posterior cingulate gyrus (Baron et al., 2001), measured through structural MRI, and hypometabolism, associated…”
Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352
“…regional microstructure from asymptomatic adults found that the neuroinflammatory markers were associated with markers of axonal damage and altered microstructure on diffusion tensor imaging (DTI) (Melah et al., 2016), suggesting that neuroinflammation worsens white matter damage in preclinical AD.”
BackgroundDupont, A.-C., Largeau, B., Santiago Ribeiro, M., Guilloteau, D., Tronel, C., & Arlicot, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040785 · Cited by 182
“These results are consistent with the presence of neuroinflammatory biomarkers in the cerebrospinal fluid of pre-symptomatic AD subjects [116].”
ResultBiomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Metadata
- Authors
- Melah, K. E., Lu, S. Y.-F., Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., Dowling, N. M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., & Bendlin, B. B.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-02-02
- Volume
- 50
- Issue
- 3
- Pages
- 873-886
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2298142461
- Cited by
- 111
- References
- 33
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.